Biopharma Leaders Unite To Stand With Science LEARN MORE Pfizer & BioNTech to Supply Singapore with Vaccine Candidate to Combat COVID-19 LEARN MORE PFIZER INVESTS $120MIL IN BIOTECH INNOVATION LEARN MORE Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027 LEARN MORE AGREEMENT REACHED WITH COVAX FOR ADVANCE PURCHASE OF COVID-19 VACCINE LEARN MORE RECENT PRESS RELEASES 05/08/2020 - LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer 05/08/2020 - Pfizer and BioNTech to Supply Canada with their BNT162 mRNA- Based Vaccine Candidate 31/07/2020 - Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate 28/07/2020 - Pfizer Reports Second-Quarter 2020 Results 27/07/2020 - Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study 22/07/2020 - Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2 20/07/2020 - Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data 20/07/2020 - Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2 13/07/2020 - Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2 09/07/2020 - Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance 06/07/2020 - Alibaba Cloud, Fintech Academy and Pfizer Partner to Accelerate Healthcare Innovations across Asia Pacific 01/07/2020 - Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2 30/06/2020 - FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma 30/06/2020 - European Commission Approves DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) 25/06/2020 - Pfizer Declares Third-Quarter 2020 Dividend Pagination First page « First Previous page ‹ Previous Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 Next page Next › Last page Last »